Registered outcomes25

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 25 of 25

List	Outcome	Time frame	Description
Secondary	Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values kidney injury biomarker	48 weeks	Urine podocalyxin
Secondary	Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values kidney injury biomarker	48weeks	Urine KIM-1
Secondary	Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values kidney injury biomarker	48 weeks	Urine NGAL
Secondary	Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values oxidative injury biomarker	48weeks	Serum Methylenedioxyamphetamine (MDA)
Secondary	Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values oxidative injury biomarker	48 weeks	Serum 8-OHd

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04335721/registered?page=2